Voloridge Investment Management LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Voloridge Investment Management LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 212,128 shares of the biopharmaceutical company's stock, valued at approximately $151,105,000. Regeneron Pharmaceuticals makes up approximately 0.5% of Voloridge Investment Management LLC's holdings, making the stock its 26th biggest holding. Voloridge Investment Management LLC owned approximately 0.19% of Regeneron Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $28,000. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC lifted its stake in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research reports. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Finally, Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Stock Up 0.4%

Regeneron Pharmaceuticals stock opened at $596.54 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a 50 day moving average price of $598.10 and a 200 day moving average price of $680.17. The company has a market capitalization of $64.41 billion, a PE ratio of 15.58, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the firm earned $9.55 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.